Author: admin

The below Parliamentary question was asked by David Amess on 2016-07-20.

To ask the Secretary of State for Health, what steps are being taken to ensure adoption of the National BSR and BHPR guidelines for the management of giant cell arteritis within the NHS; and whether his Department plans to assess whether the recommendations in those guidelines are being met.

David Mowat

Clinical commissioning groups (CCGs) are responsible for the provision of services for people with giant cell arteritis (GCA). Whilst it would not be appropriate for NHS England to direct CCGs to adopt a particular clinical pathway, it continues to ensure that the innovative approach developed at Southend University Hospital NHS Foundation Trust (FT) is shared and made available to clinicians.

There are a number of clinical guidelines that are available to support the prompt diagnosis and referral of patients with suspected GCA, including one produced by the Royal College of Physicians, which Professor Bhaskar Dasgupta, who developed the GCA pathway at Southend University Hospital NHS FT, helped to produce. This guidance provides a framework for disease assessment, immediate treatment and referral to specialist care. Furthermore, both the British Society for Rheumatology and the British Health Professionals in Rheumatology published guidelines on the management of polymyalgia rheumatica, a related condition, for general practitioners and rheumatologists. These encourage the prompt diagnosis and urgent management of GCA, helping to minimise GCA related vision loss.

The Specialised Rheumatology Clinical Reference Group at NHS England has developed proposals to establish local rheumatology networks. These are being implemented over a three year period to support consistent access to clinically effective therapies and to share good and innovative practice across the country. In addition, NHS England’s innovation team has invited Professor Dasgupta to contribute to the NHS Innovation Exchange Portal to ensure that this knowledge is shared.

On 24 June 2016, NHS England recently facilitated a webinar presented by Professor Dasgupta, which aimed to show how the fast-track pathway has significantly reduced the number of patients suffering sight-loss as an avoidable complication of GCA and, in addition, presents a case that this model is cost-saving, results in an increased patient quality of life, and successfully reduces the time to diagnosis in line with established clinical guidelines. NHS England promoted the webinar across the musculoskeletal community as well as to CCGs and patient groups through a wide range of communications channels.

The below Parliamentary question was asked by David Amess on 2016-07-20.

To ask the Secretary of State for Health, if he will develop and implement a national measure to (a) monitor whether patients with suspected giant cell arteritis (GCA) are being referred to a specialist within one working day and (b) ensure services are complying with the recommendation in National BSR and BHPR Guidelines for the management of GCA’s urgent referral to a specialist.

David Mowat

Clinical commissioning groups (CCGs) are responsible for the provision of services for people with giant cell arteritis (GCA). Whilst it would not be appropriate for NHS England to direct CCGs to adopt a particular clinical pathway, it continues to ensure that the innovative approach developed at Southend University Hospital NHS Foundation Trust (FT) is shared and made available to clinicians.

There are a number of clinical guidelines that are available to support the prompt diagnosis and referral of patients with suspected GCA, including one produced by the Royal College of Physicians, which Professor Bhaskar Dasgupta, who developed the GCA pathway at Southend University Hospital NHS FT, helped to produce. This guidance provides a framework for disease assessment, immediate treatment and referral to specialist care. Furthermore, both the British Society for Rheumatology and the British Health Professionals in Rheumatology published guidelines on the management of polymyalgia rheumatica, a related condition, for general practitioners and rheumatologists. These encourage the prompt diagnosis and urgent management of GCA, helping to minimise GCA related vision loss.

The Specialised Rheumatology Clinical Reference Group at NHS England has developed proposals to establish local rheumatology networks. These are being implemented over a three year period to support consistent access to clinically effective therapies and to share good and innovative practice across the country. In addition, NHS England’s innovation team has invited Professor Dasgupta to contribute to the NHS Innovation Exchange Portal to ensure that this knowledge is shared.

On 24 June 2016, NHS England recently facilitated a webinar presented by Professor Dasgupta, which aimed to show how the fast-track pathway has significantly reduced the number of patients suffering sight-loss as an avoidable complication of GCA and, in addition, presents a case that this model is cost-saving, results in an increased patient quality of life, and successfully reduces the time to diagnosis in line with established clinical guidelines. NHS England promoted the webinar across the musculoskeletal community as well as to CCGs and patient groups through a wide range of communications channels.

The below Parliamentary question was asked by David Amess on 2016-07-20.

To ask the Secretary of State for Health, what steps he is taking to promote the Fast Track Giant Cell Arteritis pathway piloted by Southend University Hospital.

David Mowat

Clinical commissioning groups (CCGs) are responsible for the provision of services for people with giant cell arteritis (GCA). Whilst it would not be appropriate for NHS England to direct CCGs to adopt a particular clinical pathway, it continues to ensure that the innovative approach developed at Southend University Hospital NHS Foundation Trust (FT) is shared and made available to clinicians.

There are a number of clinical guidelines that are available to support the prompt diagnosis and referral of patients with suspected GCA, including one produced by the Royal College of Physicians, which Professor Bhaskar Dasgupta, who developed the GCA pathway at Southend University Hospital NHS FT, helped to produce. This guidance provides a framework for disease assessment, immediate treatment and referral to specialist care. Furthermore, both the British Society for Rheumatology and the British Health Professionals in Rheumatology published guidelines on the management of polymyalgia rheumatica, a related condition, for general practitioners and rheumatologists. These encourage the prompt diagnosis and urgent management of GCA, helping to minimise GCA related vision loss.

The Specialised Rheumatology Clinical Reference Group at NHS England has developed proposals to establish local rheumatology networks. These are being implemented over a three year period to support consistent access to clinically effective therapies and to share good and innovative practice across the country. In addition, NHS England’s innovation team has invited Professor Dasgupta to contribute to the NHS Innovation Exchange Portal to ensure that this knowledge is shared.

On 24 June 2016, NHS England recently facilitated a webinar presented by Professor Dasgupta, which aimed to show how the fast-track pathway has significantly reduced the number of patients suffering sight-loss as an avoidable complication of GCA and, in addition, presents a case that this model is cost-saving, results in an increased patient quality of life, and successfully reduces the time to diagnosis in line with established clinical guidelines. NHS England promoted the webinar across the musculoskeletal community as well as to CCGs and patient groups through a wide range of communications channels.